[go: up one dir, main page]

AU2023427992A1 - Treatment of mental disorders - Google Patents

Treatment of mental disorders

Info

Publication number
AU2023427992A1
AU2023427992A1 AU2023427992A AU2023427992A AU2023427992A1 AU 2023427992 A1 AU2023427992 A1 AU 2023427992A1 AU 2023427992 A AU2023427992 A AU 2023427992A AU 2023427992 A AU2023427992 A AU 2023427992A AU 2023427992 A1 AU2023427992 A1 AU 2023427992A1
Authority
AU
Australia
Prior art keywords
treatment
mental disorders
dmt
meo
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023427992A
Inventor
Conor Burke
Naoise GAFFNEY
Theis Terwey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GH Research Ireland Ltd
Original Assignee
GH Research Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2023/057885 external-priority patent/WO2023186837A1/en
Application filed by GH Research Ireland Ltd filed Critical GH Research Ireland Ltd
Priority claimed from PCT/EP2023/076819 external-priority patent/WO2024160391A1/en
Publication of AU2023427992A1 publication Critical patent/AU2023427992A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in the treatment of a mental or nervous system disorder in a mother having a child of age 18 months or below, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.
AU2023427992A 2023-01-30 2023-09-27 Treatment of mental disorders Pending AU2023427992A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP23154014 2023-01-30
EP23154014.7 2023-01-30
EP23153996 2023-01-30
EP23153996.6 2023-01-30
PCT/EP2023/057885 WO2023186837A1 (en) 2022-03-27 2023-03-27 Treatment of postnatal depression
AUPCT/EP2023/057874 2023-03-27
AUPCT/EP2023/057885 2023-03-27
PCT/EP2023/057874 WO2023186827A1 (en) 2022-03-27 2023-03-27 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression
PCT/EP2023/076819 WO2024160391A1 (en) 2023-01-30 2023-09-27 Treatment of mental disorders

Publications (1)

Publication Number Publication Date
AU2023427992A1 true AU2023427992A1 (en) 2025-09-18

Family

ID=96878788

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2023427992A Pending AU2023427992A1 (en) 2023-01-30 2023-09-27 Treatment of mental disorders
AU2023428136A Pending AU2023428136A1 (en) 2023-01-30 2023-09-27 5-meo-dmt for use in the treatment of postpartum depression

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023428136A Pending AU2023428136A1 (en) 2023-01-30 2023-09-27 5-meo-dmt for use in the treatment of postpartum depression

Country Status (5)

Country Link
KR (2) KR20250138805A (en)
CN (2) CN120813347A (en)
AU (2) AU2023427992A1 (en)
IL (2) IL322427A (en)
MX (2) MX2025008749A (en)

Also Published As

Publication number Publication date
KR20250138805A (en) 2025-09-22
MX2025008749A (en) 2025-10-01
IL322427A (en) 2025-09-01
AU2023428136A1 (en) 2025-09-18
KR20250134717A (en) 2025-09-11
CN120641095A (en) 2025-09-12
MX2025008750A (en) 2025-11-03
IL322430A (en) 2025-09-01
CN120813347A (en) 2025-10-17

Similar Documents

Publication Publication Date Title
AU2023427437A1 (en) 5-methoxy-n,n-dimethyltryptamine for use in the treatment of mental disorders in breastfeeding mothers
Assis et al. Novel insights to enhance therapeutics with acyclovir in the management of herpes simplex encephalitis
Citron et al. Patient-controlled analgesia for cancer pain: a long-term study of inpatient and outpatient use
AU2023427992A1 (en) Treatment of mental disorders
Geller Meperidine in patient-controlled analgesia: a near-fatal mishap
Douglas et al. Prolonged intrathecal baclofen withdrawal syndrome: case report and discussion of current therapeutic management
Andriole Pharmacokinetics of cephalosporins in patients with normal or reduced renal function
Apodaca et al. Ertapenem-induced delirium: a case report and literature review
Aricó et al. Severe acute encephalopathy following inadvertent intrathecal doxorubicin administration
Steinman et al. Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis
Choi et al. Cerebral salt wasting treated with fludrocortisone in a 17-year-old boy
Scott et al. Pharmacological management of convulsive status epilepticus in children
Shah et al. Cefepime-induced encephalopathy with seizures in a pediatric patient with end-stage renal disease rapidly reversed by high-efficiency hemodialysis
Smith Anesthestic agents and status epilepticus
Kesecioglu et al. Effect of aminophylline or physostigmine on recovery from nitrous oxide‐enflurane anaesthesia
Gjerris Transitory procaine-induced parkinsonism
Cheng Intranasal midazolam for rapidly sedating an adult patient
Yanaral et al. Rhinorrhea due to infusion of Dexmedetomidine during Rhinoplasty: a Case Report and current literature review
Weiss et al. Value of chlorpromazine in preoperative medication
Farid et al. Effects of Dexmedetomidine and Fentanyl on Post-Operative Cognitive Function
Fang et al. Extracorporeal membrane oxygenation and sustained low-efficiency diafiltration successfully resuscitated propofol infusion syndrome during refractory status epilepticus
Okayasu Sodium valproate
Dhamija Neurotoxicity: case report
Gonty Ketamine: A new look at an old drug
Vinogradov et al. Propofol-based protocol of general anesthesia for operations in patients with severe burns with ASA class III-IV